Maldives

Country Fact Sheet

Epidemic

Prevalence of Hepatitis B

- General Population: 0.8%
- Blood Donors: 0%
- Antenatal Clients: 0%
- MSM: 0.8%
- PWID: 6%
- CSW: 0%
- PLHIV: 0%

Prevalence of Hepatitis C

- General Population: 0.7%
- Blood Donors: 0%
- Antenatal Clients: 0%
- MSM: 0%
- PWID: 0%
- CSW: 0%
- PLHIV: 0%

Source: BSS (2008), National HIV register
*Blue – representative sample; **Red – non-representative sample; MSM – men who have sex with men and PWID – people who inject drugs

Policies

Hepatitis B vaccine
- Birth dose of Hep B vaccine - YES
- Hep B immunization included in routine infant immunization schedule - YES
- Vaccination for HCWs - NO
- Vaccination for high risk groups (key populations) - YES

Hepatitis testing
- Is there official guidance for diagnosing HBV - NO
- Is there official guidance for diagnosing HCV - NO

Blood & Injection safety
- Donated blood screened for Hep B & Hep C - YES
- Use of RUP syringes - YES
- Needle and syringe distribution program for PWID - YES

Mortality

Maldives

- Acute Hepatitis B: 9%
- Liver cancer HBV: 36%
- Cirrhosis HBV: 55%

Source: WHO GHE, 2016

Access to medicines

- Availability of medicines for Hep B treatment: Available
- Annual cost for Hep B treatment: USD 168

- Availability of DAAs for Hep C treatment: Not Available

Health sector response

- National Plan for viral hepatitis: NO
- Coverage of 3-dose Hep B vaccine schedule (2014): 98%
- Coverage of Hep B vaccine for newborns: 99%
- Estimate of facilities offering serological testing (HBsAg) for HBV: 91
- Estimate of facilities offering nucleic acid testing (NAT) for HBV: 0
- Estimate of facilities offering serological testing (Anti-HCV) for HCV: 91
- Estimate of facilities offering nucleic acid testing (NAT) for HCV: 0

Source: Country survey
Abbreviations: HCWS- health care workers, PLHIV – people living with HIV, RUP – re-use prevention

July 2018
World Health Organization, South-East Asia Region